Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PTPN2 inhibitor ABBV-CLS-484

An orally bioavailable inhibitor of the T-cell specific tyrosine-protein phosphatase non-receptor type 2 (PTPN2), with potential immunomodulating and antineoplastic activities. Upon oral administration, PTPN2 inhibitor ABBV-CLS-484 specifically targets and binds to PTPN2. This prevents PTPN2-mediated signal transduction pathways and may activate anti-tumor T-cell immune responses. It may also sensitize tumor cells to immunotherapeutics. PTPN2 negatively regulates TCR and cytokine signaling needed for T-cell function, homeostasis and differentiation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	ABBV CLS 484 ABBV CLS-484 ABBV CLS484

PTPN2 inhibitor ABBV-CLS-484

Search NCI's Drug Dictionary